Whitehawk Therapeutics to Showcase Innovations at Major Investor Conferences

Upcoming Investor Conferences for Whitehawk Therapeutics

Whitehawk Therapeutics, Inc., a prominent clinical-stage company specializing in oncology therapeutics, is gearing up to make appearances at several key investor conferences as part of its mission to advance cancer treatment technologies. The participation underscores the firm’s commitment to driving innovation in antibody-drug conjugates (ADCs) designed to better target and treat challenging cancers.

Conference Schedule

1. TD Cowen 46th Annual Health Care Conference
Dave Lennon, PhD, the President and CEO of Whitehawk, will be participating in a hybrid presentation and live discussion at this significant event on Tuesday, March 3, at 10:30 AM ET. This setting will provide an excellent opportunity for investors to engage with the leadership and understand the strategies and technologies that Whitehawk is deploying in the oncology space.

2. Leerink 2026 Global Healthcare Conference
Scheduled for Monday, March 9, Whitehawk’s executives will be involved in investor meetings, ensuring investors can gain insights into the company’s developments and strategic visions. This conference represents an ideal platform for networking and investor engagement.

3. Citizens Life Sciences Conference
Concluding the conference participation, Dr. Lennon will present Whitehawk's corporate vision on Tuesday, March 10, at 12:30 PM ET. This session will further delve into the company's pipeline and partnerships, focusing on how they are poised to transform cancer treatment paradigms.

Accessing Presentations

For those interested in the insights shared during these conferences, Whitehawk Therapeutics will offer a live webcast of both the TD Cowen and Citizens presentations. Investors and interested parties can access these webcasts on the Whitehawk Therapeutics Investor Relations website where recordings will be available for approximately 30 days post-event.

About Whitehawk Therapeutics

Founded with a mission to innovate within the oncology space, Whitehawk Therapeutics is dedicated to advancing cancer treatments through cutting-edge technologies. The company specializes in improving ADCs, navigating the complexities of tumor biology to enable effective treatments that deliver meaningful patient impact. Their three-asset ADC portfolio, licensed exclusively from WuXi Biologics, aims to surpass the limitations of prior-generation therapies and achieve significant breakthroughs for patients with complex tumors.

For more information about the firm and its projects, visitors are encouraged to explore their website at www.whitehawktx.com where further updates and news releases can be found. Additionally, follow Whitehawk Therapeutics on LinkedIn for real-time updates and insights into their therapeutic advancements.

Conclusion

As Whitehawk Therapeutics actively participates in these significant investor conferences, the outlook on their innovative approaches and corporate partnerships becomes increasingly pertinent. The company is positioning itself to engage with stakeholders effectively, ensuring that the advancements in cancer treatment technologies reach those who need them the most.